Kangasniemi P, Andersen A R, Andersson P G, Gilhus N E, Hedman C, Hultgren M, Vilming S, Olesen J
Department of Neurology, University Hospital, Turku, Finland.
Cephalalgia. 1987 Dec;7(4):231-8. doi: 10.1046/j.1468-2982.1987.0704231.x.
Metoprolol slow-release tablets (Durules), 200 mg, given once daily in the morning were compared with placebo in the prophylaxis of classic migraine. The trial comprised eight Scandinavian neurologic centres and was designed as a double-blind cross-over study with 4 weeks' run-in, four weeks washout, and 8 weeks of either treatment. Seventy-seven patients with two to eight migraine attacks per month were entered in the trial, and 73 completed it. A total of 1119 attacks with aura symptoms and 374 without were recorded. Metoprolol was significantly better than placebo with regard to the total frequency of attacks (1.8 versus 2.5 attacks/4 weeks), mean duration of attacks (6.0 versus 8.0 h/attack), mean global rating, and consumption of analgesics per attack. Similar differences could be shown for attacks with aura symptoms alone, except for the duration of attacks. Metoprolol is the first drug for which a prophylactic effect in classic migraine has been convincingly demonstrated.
将美托洛尔缓释片(倍他乐克缓释片)200毫克,每日早晨服用一次,与安慰剂进行比较,以预防典型偏头痛。该试验由八个斯堪的纳维亚神经学中心参与,设计为双盲交叉研究,包括4周的导入期、4周的洗脱期以及8周的治疗期。77名每月有2至8次偏头痛发作的患者参与了试验,73名患者完成了试验。共记录了1119次伴有先兆症状的发作和374次无先兆症状的发作。在发作总频率(1.8次/4周对2.5次/4周)、平均发作持续时间(6.0小时/次对8.0小时/次)、平均总体评分以及每次发作的镇痛药消耗量方面,美托洛尔明显优于安慰剂。对于仅伴有先兆症状的发作,除发作持续时间外,也可显示出类似差异。美托洛尔是第一种在典型偏头痛预防方面已被令人信服地证明有预防作用的药物。